Related Experiment Video
Updated: Feb 18, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Challenges in Ras therapeutics in pancreatic cancer
Minsig Choi1, Harold Bien1, Adaobi Mofunanya2
1Division of Hematology/Oncology, Stony Brook University, Stony Brook, NY, United States.
Abstract:
Pancreatic cancer is considered among the most aggressive and the least curable of all human malignancies. It is usually characterized by multiple aberrations in tumor suppressor genes and oncogenes, most notably activating mutations in KRAS. This review examines the various attempts that have been made to inhibit Kras and its downstream signaling pathways in pancreatic cancer with an emphasis on challenges related to clinical trials. Attempts include preventing the localization of Ras protein to the plasma membrane, inhibiting downstream oncogenic signaling by targeting Kras effectors such as MEK1/2, Erk1/2 or Akt singly or in combination, and directly inhibiting Kras protein. Most clinical trials have focused on inhibiting downstream effector pathways and clinical benefit has been limited due to compensatory mechanisms and toxicity associated with small therapeutic windows. Additionally, genetic screens have been conducted to identify gene or genes that could provide therapeutic vulnerabilities in mutant KRAS cells and provide a way to target mutant Kras protein only. We also discuss how potentially transforming clinical trials have failed in the past and what new strategies are on-going in clinical trials for pancreas cancer. For long-term success in targeting Kras, future efforts should focus on combinatorial strategies to more effectively block Kras pathways at multiple points, and improve translational application of pre-clinical data to the clinic.
Insights
Targeting KRAS mutations in pancreatic cancer is challenging. This review explores strategies to inhibit KRAS signaling pathways, highlighting clinical trial limitations and future combinatorial approaches for improved efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Pancreatic cancer is highly aggressive and difficult to treat, often driven by KRAS mutations.
- KRAS mutations are a hallmark of pancreatic ductal adenocarcinoma, necessitating targeted therapeutic strategies.
- Current treatments for pancreatic cancer have limited efficacy, underscoring the need for novel therapeutic interventions.
Purpose of the Study:
- To review various strategies aimed at inhibiting KRAS and its downstream signaling pathways in pancreatic cancer.
- To analyze the challenges and limitations encountered in clinical trials targeting KRAS.
- To discuss emerging therapeutic vulnerabilities and future directions for KRAS-targeted therapies in pancreatic cancer.
Main Methods:
- Review of preclinical and clinical studies investigating KRAS inhibition strategies.
- Analysis of approaches targeting Ras protein localization, downstream effectors (MEK, Erk, Akt), and direct KRAS inhibition.
- Examination of genetic screening methods to identify therapeutic vulnerabilities in KRAS-mutant cells.
Main Results:
- Inhibition of downstream effector pathways has shown limited clinical benefit due to compensatory mechanisms and toxicity.
- Directly inhibiting KRAS or preventing its membrane localization presents significant therapeutic challenges.
- Genetic screens are identifying potential targets for selective KRAS inhibition in cancer cells.
Conclusions:
- Targeting KRAS in pancreatic cancer requires overcoming significant hurdles related to pathway redundancy and drug toxicity.
- Future strategies should focus on combinatorial approaches to block KRAS pathways at multiple points.
- Improved translation of preclinical findings to clinical applications is crucial for developing effective KRAS-targeted therapies.
Related Concept Videos
02:38The Ras Gene
Ras is a...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...